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Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver damage and has a strong genetic component. The
rs4841132 G>A variant, modulating the expression of protein phosphatase 1 regulatory subunit 3B (PPP1R3B), which is
involved in glycogen synthesis, has been reported to reduce the risk of NAFLD but at the same time may favor liver dis-
ease by facilitating glycogen accumulation. The aim of this study was to assess the impact of rs4841132 on development of
histologic steatosis and fibrosis in 1,388 European individuals in a liver biopsy cohort, on NAFLD hepatocellular carci-
noma in a cross-sectional Italian cohort (n 5 132 cases), and on liver disease at the population level in the United King-
dom Biobank cohort. We investigated the underlying mechanism by examining the impact of the variant on gene
expression profiles. In the liver biopsy cohort, the rs4841132 minor A allele was associated with protection against steatosis
(odds ratio [OR], 0.63; 95% confidence interval [CI], 0.42-0.95; P 5 0.03) and clinically significant fibrosis (OR, 0.35;
95% CI, 0.14-0.87; P 5 0.02) and with reduced circulating cholesterol (P 5 0.02). This translated into protection against
hepatocellular carcinoma development (OR, 0.22; 95% CI, 0.07-0.70; P 5 0.01). At the population level, the rs4841132
variation was not associated with nonalcoholic or nonviral diseases of the liver but was associated with lower cholesterol (P
5 1.7 3 10–8). In individuals with obesity, the A allele protecting against steatosis was associated with increased
PPP1R3B messenger RNA expression and activation of lipid oxidation and with down-regulation of pathways related to
lipid metabolism, inflammation, and cell cycle. Conclusion: The rs4841132 A allele is associated with protection against
hepatic steatosis and fibrosis in individuals at high risk of NAFLD but not in the general population and against dyslipi-
demia. The mechanism may be related to modulation of PPP1R3B expression and hepatic lipid metabolism. (Hepatology
Communications 2018;2:666-675)
Nonalcoholic fatty liver disease (NAFLD) isbecoming a leading cause of liver damageworldwide.(1) NAFLD pathogenesis is
strongly intertwined with excessive adiposity, insulin
resistance, and dyslipidemia.(2) Dietary factors, such as
alcohol, fructose, and physical activity, are other major
risk factors for this condition.(3) NAFLD has a strong
genetic component, and variants in proteins regulating
hepatocellular lipid handling, including patatin-like
phospholipase domain-containing 3 (PNPLA3),
transmembrane 6 superfamily member 2 (TM6SF2),
membrane bound O-acyltransferase domain-contain-
ing 7 (MBOAT7), and glucokinase regulator (GCKR),
predispose to the development and progression to non-
alcoholic steatohepatitis (NASH), which is the inflam-
matory form of NAFLD, and to hepatic fibrosis,(4,5)
Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; kb, kilobase; LBC, liver biopsy cohort; NAFLD, Nonalcoholic fatty liver dis-
ease; NASH, nonalcoholic steatohepatitis; OR, odds ratio; PPP1R3B, protein phosphatase 1 regulatory subunit 3B.
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which is the major prognostic determinant in patients
with NAFLD.(6) By exploiting naturally occurring var-
iation at these loci, we recently highlighted by a Men-
delian randomization approach that hepatic fat
accumulation is a key driver of liver disease progression
and fibrosis development in at-risk individuals.(7)
However, whether this is generalizable to other risk
factors for NAFLD development and progression and
for protective variants remains to be demonstrated.
Protein phosphatase 1 regulatory subunit 3B
(PPP1R3B) has been identified as another locus associated
with hepatic fat content, as estimated by computed
tomography in genome-wide association studies.(8)
PPP1R3B encodes for a protein involved in glycogen syn-
thesis.(9) Subsequent studies have been consistent with the
hypothesis that the rs4240624 variant, which is located
175 kilobase (kb) upstream of the PPP1R3B coding
region, associates with reduced fat as estimated by
ultrasonography(10,11) and with increased hepatic glycogen
content.(12) However, when liver fat was directly measured
by histology, the association with the PPP1R3B variation
was not confirmed.(8,13) Furthermore, Stender et al.(9)
showed that the minor allele of rs4841132, which is in
complete linkage disequilibrium with rs4240624, was
associated with increased X-ray attenuation but not with
decreased hepatic fat content in population studies. On
the contrary, the minor A allele was associated with
increased aminotransferases and liver disease.(9) Therefore,
the overall impact of the PPP1R3B variation on hepatic
fat and progressive liver damage remains controversial.
Within this context, we evaluated the impact of the
rs4841132 G>A variant, located in LOC157273, 175
kb upstream of the PPP1R3B gene, on a histologic
steatosis, metabolic profile and on liver damage in a
large cohort of European individuals.(14) In addition,
we evaluated the impact of the variant on liver
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diagnoses in the publicly available United Kingdom
Biobank cohort. Finally, we explored the mechanism
underlying the epidemiological association by examin-
ing the impact of the variant on gene expression
profiles.
Patients and Methods
THE LIVER BIOPSY COHORT
The liver biopsy cohort (LBC) has been
described.(5,15) A total of 1,388 adult individuals of
European descent were consecutively enrolled from the
Metabolic Liver Diseases outpatient service and
bariatric surgery center, Fondazione IRCCS Ca’
Granda Ospedale Policlinico Milano, Milan, Italy, and
from the Northern Savo Hospital District, Kuopio,
Finland. Inclusion criteria were availability of a liver
biopsy for suspected NASH or severe obesity, DNA
samples, and clinical data. Individuals with excessive
alcohol intake (men, >30 g/day; women, >20 g/day),
viral and autoimmune hepatitis, or other causes of liver
disease were excluded. The study conformed to the
Declaration of Helsinki and was approved by the
Institutional Review Board of the Fondazione Ca’
Granda IRCCS of Milan and relevant Institutions. All
participants gave written informed consent. The
clinical features of individuals evaluated in the study
are presented in Table 1.
TABLE 1. DEMOGRAPHIC, ANTHROPOMETRIC, AND CLINICAL FEATURES OF THE LIVER BIOPSY
COHORT STRATIFIED FOR ENROLLMENT CRITERIA (LIVER CLINIC, BARIATRIC SURGERY) AND THE
NAFLD-HCC COHORT
Liver Biopsy Cohort
(N 5 1,388)
Liver Clinic Bariatric Surgery NAFLD-HCC
(n 5 509) (n 5 879) (n 5 132) P Value* P Value†
Sex, M 409 (80) 218 (25) 101 (77) <0.0001 <0.0001
Age, years 49.9 6 12.4 44.9 6 10.3 67.5 6 1.05 <0.0001 <0.0001
BMI, kg/m2 28.4 6 4.4 42.3 6 6.7 29.3 6 0.8 <0.0001 <0.0001
T2D, yes 111 (22) 227 (26) 76 (58) 0.06 <0.0001
Total cholesterol, mg/dL 201.1 6 42.5 185.6 6 46.4 170 6 7.7 <0.0001 <0.0001
LDL cholesterol, mg/dL 124 6 38.6 108.2 6 38.6 100.5 6 7.7 <0.0001 0.0008
HDL cholesterol, mg/dL 46.4 6 15.4 50.3 6 19.3 50.2 6 3.9 0.41 0.61
Triglycerides, mg/dL 148.7 6 78.7 139.9 6 69.9 139.9 6 017.5 0.03 0.79
ALT, IU/L‡ 47 (29-74) 30 (23-41) 45 (28-69) <0.0001 0.11
AST, IU/L‡ 20 (16-27) 27 (18-42) 44 (30-61) <0.0001 <0.0001
PNPLA3, I148M <0.0001 <0.0001
I/I 180 (35.4) 464 (52.8) 31 (23.5)
I/M 227 (44.6) 317 (36) 54 (419
M/M 101 (19.8) 70 (8) 49 (37)
TM6SF2, E167K 0.003 0.59
E/E 431 (84.7) 757 (86.1) 113 (85.6)
E/K 70 (13.8) 87 (9.9) 19 (14.4)
K/K 8 (1.6) 2 (0.2) 2 (1.5)
MBOAT7, rs641738 C>T 0.98 0.04
C/C 179 (35) 295 (34) 28 (21.2)
C/T 225 (44) 367 (42) 69 (52.2)
T/T 105 (21) 172 (20) 35 (26.5)
GCKR, P446L 0.0001 0.64
C/C 112 (22) 215 (24) 32 (24.2)
C/T 235 (46) 368 (42) 65 (49.2)
T/T 162 (32) 171 (19) 33 (25)
PPP1R3B, rs4841132 G>A 0.01 0.04
G/G 433 (85) 698 (79) 124 (93.9)
G/A 72 (14) 173 (20) 8 (6.1)
A/A 4 (0.8) 8 (0.9) 0
Values are reported as mean 6 SD and number (%), except where noted. *Liver clinic versus bariatric surgery; †Milan liver biopsy
cohort versus Italian NAFLD-HCC cohort; ‡median (interquartile range).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GCKR, glucokinase regulator;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; MBOAT7, membrane bound O-acyltransferase domain-containing 7;
PNPLA3, patatin-like phospholipase domain-containing 3; T2D, type 2 diabetes; TM6SF2, transmembrane 6 superfamily member 2.
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HISTOLOGIC AND LIVER
DAMAGE EVALUATION
Steatosis was graded into the following four catego-
ries based on the percentage of affected hepatocytes: 0,
0%-4%; 1, 5%-32%; 2, 33%-65%; and 3, 66%-100%.
Disease activity was assessed according to the NAFLD
activity score, with systematic evaluation of hepatocel-
lular ballooning and necroinflammation; fibrosis was
also staged according to the recommendations of the
NAFLD Clinical Research Network.(16) The scoring
of liver biopsies was performed by independent pathol-
ogists unaware of patient status and genotype.(15,17)
NASH was diagnosed in the presence of steatosis, lob-
ular necroinflammation, and hepatocellular ballooning.
NAFLD-HEPATOCELLULAR
CARCINOMA COHORT
Part of the NAFLD-hepatocellular carcinoma
(NAFLD-HCC) cohort of the exome sequencing for
the identification of inherited variants associated with
hepatocellular carcinoma in NAFLD (EPIDEMIC-
NAFLD) study has been described.(18,19) Briefly, this is
a case-control study in which we genotyped Italian
patients with NAFLD-HCC and compared the fre-
quency of risk variants with healthy individuals and
with controls with advanced fibrosis due to NAFLD.
The NAFLD-HCC patients of Italian descent were
enrolled between January 2008 and January 2015 at the
Milan, Udine, Turin, Rome, and Palermo hospitals.
Diagnosis of HCC was based on the European Associ-
ation for the Study of the Liver –European Organiza-
tion for Research and Treatment of Cancer Clinical
Practice Guidelines.(20) In the absence of liver biopsy,
diagnosis of NAFLD required detection of ultrasono-
graphic steatosis plus at least one criterion of the meta-
bolic syndrome. Clinical features of these individuals
are presented in Table 1.
GENOTYPING
The LBC cohort was genotyped for the rs738409
C>G (PNPLA3 I148M), rs58542926 C>T (TM6SF2
E167K), rs1260326 C>T (GCKR P446L), rs641738
C>T MBOAT7, and rs4841132 G>A (LOC157273-
PPP1R3B) variants as described.(5,15) Genotyping of
the LBC was performed in duplicate using TaqMan 50-
nuclease assays (Life Technologies, Carlsbad, CA).
Genotype frequencies of the four variants were in agree-
ment with Hardy-Weinberg proportions (P > 0.1).
UNITED KINGDOM BIOBANK
COHORT
The associations of the rs4841132 variant with phe-
notype related to metabolic disorders and liver disease
were evaluated in the United Kingdom Biobank
cohort, a prospective population study of half a million
subjects not selected for liver diseases. These subjects
were identified at 22 centers across the United King-
dom during 2006 to 2010, and almost all were aged
40-69 years old. Freely available basic association data
were downloaded from Neale Lab (http://geneatlas.
roslin.ed.ac.uk).
TRANSCRIPTOMIC ANALYSIS
Gene expression was measured in a subset of 125
patients with obesity belonging to the Milan cohort,
after percutaneous liver biopsy performed during
bariatric surgery. Their clinical features are presented
in Supporting Table S1. Total RNA was isolated using
the miRNeasy mini-kit (Qiagen, Hulsterweg, Ger-
many), according to the manufacturer’s instructions.
RNA quality was assessed using the Agilent 2100 Bio-
analyzer, and samples with RNA integrity numbers
greater than or equal to 7 were used for library prepara-
tion. RNA sequencing was performed in paired-end
mode with a read length of 150 nucleotides using the
Illumina HiSeq 4000 (Novogene, Hong Kong,
China). Raw reads were mapped against the Human
Genome,(21) using a custom pipeline based on the
standard primary analysis procedure. The pipeline per-
formed the primary analysis step, including FASTQ
quality check (FastQC software; Babraham Bioinfor-
matics, Cambridge, United Kingdom), low-quality
reads trimming with Trimmomatic,(22) and mapping
on the GRCh37 reference genome using STAR map-
per.(23) RNA sequencing quality control was per-
formed, and samples with <10 million reads uniquely
mapped or with <60% uniquely mapped/mapped
reads were excluded from the analysis. Gene reads
count (Ensemble human transcript reference assembly,
version 75) was performed using RSEM software.(24)
To quantify gene expression, RSEM per gene counts
were normalized using the DESeq2 package.(25)
STATISTICAL ANALYSIS
For descriptive statistics, continuous variables were
shown as mean and SD or median and interquartile
range for highly skewed biological variables. Variables
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with skewed distributions were log-transformed before
analyses. Categorical variables were presented as num-
ber and proportion. All genetic analyses were per-
formed under additive models.
Analyses were performed by fitting data into gener-
alized linear regression models. In particular, general
linear models were fit to examine continuous traits.
Logistic regression models were fit to examine binary
traits (NASH, severe fibrosis stage F3-F4), and ordinal
regression models were fit for ordinal traits (compo-
nents of the NAFLD activity score: severity of steato-
sis, necroinflammation and hepatocellular ballooning,
stage of fibrosis). When specified, confounding factors
(including recruitment center) were included in a
model.
Statistical analyses were carried out using JMP 13.0
(SAS Institute, Cary, NC) and R statistical analysis
software, version 3.3.2 (http://www.R-project.org/). P
< 0.05 (two-tailed) was considered statistically
significant.
Results
PPP1R3B GENE VARIATION IS
ASSOCIATED WITH
PROTECTION AGAINST
HISTOLOGIC STEATOSIS
The frequency distribution of the rs4841132 G>A
variant was in Hardy-Weinberg equilibrium (P 5
0.75; Supporting Table S2). The independent predic-
tors of liver damage in the liver biopsy cohort are
shown in Table 2. Logistic regression analysis adjusted
for sex, age, body mass index, type 2 diabetes mellitus,
indication for liver biopsy, and known genetic risk var-
iants for NAFLD showed the rs4841132 minor A
allele was associated with protection against steatosis
(OR, 0.63; 95% confidence interval [CI], 0.42-0.95; P
5 0.03) and against clinically significant fibrosis (OR,
0.35; 95% CI, 0.14-0.87; P 5 0.02). With ordinal
regression analysis adjusted as above, the minor A
allele was associated with reduced steatosis grade
TABLE 2. INDEPENDENT PREDICTORS OF LIVER DAMAGE (PRESENCE OF STEATOSIS, NASH, AND
FIBROSIS STAGE F2-F4) IN THE LIVER BIOPSY COHORT
Steatosis NASH Fibrosis F2-F4
OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
Age, years 1.02 0.99-1.04 0.07 1.01 1.00-1.02 0.09 1.05 1.03-1.08 <0.001
Sex, M 1.49 0.94-2.39 0.09 1.61 1.19-2.17 0.002 0.99 0.54-1.84 0.99
BMI, kg/m2 1.07 1.03-1.10 <0.001 1.07 1.04-1.09 <0.001 1.03 0.99-1.08 0.17
IFG/T2DM, yes 2.18 1.29-3.67 0.004 2.06 1.49-2.86 <0.001 3.43 1.93-6.11 <0.001
PNPLA3, I148M alleles 1.39 1.02-1.90 0.04 1.51 1.25-1.82 <0.001 2.24 1.54-3.26 <0.001
TM6SF2, E167K 1.62 0.83-3.13 0.16 1.88 1.32-2.68 <0.001 1.58 0.80-3.09 0.19
MBOAT7 rs641738 T 1.06 0.82-1.39 0.65 1.06 0.89-1.27 0.48 0.91 0.61-1.33 0.62
GCKR, L446P 1.06 0.80-1.39 0.69 1.05 0.88-1.25 0.62 0.77 0.53-1.12 0.17
PPP1R3B, rs4841132 A alleles 0.63 0.42-0.95 0.03 0.79 0.57-1.09 0.16 0.35 0.14-0.87 0.02
Logistic regression models were used to test the association of demographic, clinical, and genetic factors with liver damage. In addition
to the predictors shown above, models were adjusted for indication for liver biopsy (severe obesity versus increased liver enzymes in
NAFLD).
Abbreviations: BMI, body mass index; GCKR, glucokinase regulator; IFG, impaired fasting glucose; MBOAT7, membrane bound
O-acyltransferase domain-containing 7; PNPLA3, patatin-like phospholipase domain-containing 3; TM6SF2, transmembrane 6
superfamily member 2; T2DM: type 2 diabetes mellitus.
                                                                 
FIG. 1. In the LBC, the PPP1R3B rs4841132 variant is associ-
ated with protection against steatosis development. The associa-
tion between the PPP1R3B rs4841132 variant and the risk of
NAFLD was tested by multivariate ordinal regression analysis
adjusted for age, sex, body mass index, presence of impaired fast-
ing glucose/type 2 diabetes mellitus, PNPLA3 I148M alleles,
presence of the TM6SF2 E167K variant, MBOAT7/TMC4 T
allele, GCKR P446L variant, and indication of liver biopsy
(severe obesity versus nonalcoholic fatty liver with increased liver
enzymes. Abbreviations: AA, homozygotes for the A allele
(carriers); GA, heterozygotes; GG, homozygotes for the G allele.
                                                                 
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(estimated beta, –0.36; 95% CI, –0.64 to –0.08; P 5
0.01; Fig. 1).
Findings were generally consistent after stratification
of patients for the enrollment criteria. The rs4841132
A allele was associated with protection against fibrosis
(OR, 0.26; 95% CI, 0.08-0.80; P 5 0.02) in the liver
clinic cohort (Supporting Table S3). In the bariatric
cohort, the A allele was associated with protection
against steatosis (OR, 0.61; 95% CI, 0.40-0.93; P 5
0.02; Supporting Table S3; estimated beta, –0.50; 95%
CI, –0.86 to –0.15; P 5 0.006; Supporting Fig. S1A)
and lobular inflammation (estimated beta –0.41; 95%
CI, –0.83 to –0.02; P 5 0.04; Supporting Fig. S1A).
In the overall series of patients at risk of NASH, the
A allele was associated with reduced total and high-
density lipoprotein cholesterol (P < 0.05; Table 3).
After stratification for enrollment criteria, the impact
of the variant on circulating lipids was larger in the
bariatric cohort (Supporting Table S4).
PPP1R3B GENE VARIATION IS
ASSOCIATED WITH REDUCED
RISK OF NAFLD-HCC
To examine the impact of the variant on specific
clinically relevant outcomes, we assessed the associa-
tion with NAFLD-HCC in the Italian EPIDEMIC
case controls (n 5 132 cases, n 5 995 controls) whose
characteristics and prevalence of the PPP1R3B variant
are shown in Table 1 and Fig. 2. The independent
predictors of NAFLD-HCC are reported in Table 4.
We detected a reduced frequency of the minor A allele
in patients with HCC than in those without HCC (P
5 0.02; Fig. 2), and the minor A allele was indepen-
dently associated with protection against HCC devel-
opment (OR, 0.22; 95% CI, –2.6 to –0.4; P 5 0.01).
Notably, the protective effect of the variant seemed to
depend on liver disease severity as adjustment for
advanced fibrosis abolished the association of the A
allele with NAFLD-HCC (Table 4). These findings
TABLE 3. DEMOGRAPHIC, ANTHROPOMETRIC, AND CLINICAL FEATURES OF THE LIVER BIOPSY
COHORT (N 5 1,388) STRATIFIED BY PPP1R3B rs4841132 GENOTYPE
GG
(n 5 1,131)
GA
(n 5 245)
AA
(n 5 12) P Value*
Sex, M 522 (46) 100 (41) 5 (42) 0.36
Age, years 47 6 11 47 6 11 54 6 6 0.12
BMI, kg/m2 37 6 9 38 6 8 38 6 7 0.64
IFG/T2D, yes 276 (24) 60 (24) 2 (17) 0.08
HOMA-IR 6.2 6 15 6.9 6 13 4.1 6 1.9 0.92
Insulin, IU/mL 22 6 33 23 6 27 17 6 7.6 0.99
Total cholesterol, mg/dL 193.3 6 42.5 181.7 6 42.5 170.1 6 50.3 0.02
LDL cholesterol, mg/dL 116 6 38.6 112.1 6 38.6 96.7 6 34.8 0.18
HDL cholesterol, mg/dL 50.3 6 15.5 46.4 6 11.6 46.4 6 11.6 0.03
Triglycerides, mg/dL 139.9 6 78.7 131.2 6 61.2 113.7 6 35 0.07
ALT, IU/L† 32 (20-54) 36 (24-55) 32 (22-43) 0.78
AST, IU/L† 24 (18-34) 26 (20-36) 27 (21-40) 0.87
Values are reported as mean 6 SD or number (%), except where indicated. Characteristics of participants were compared across
rs236918 genotypes using linear regression model (for continuous characteristics) or logistic regression model (for categorical character-
istics). *Models were adjusted for sex, age, BMI, PNPLA3 I148M alleles, TM6SF2 E167K alleles, MBOAT7 rs641738 T, GCKR
P446L variant and statin use. †median (IQR).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HDL, high-density lipopro-
tein; HOMA-IR, homeostasis model assessment of insulin resistance; IFG, impaired fasting glucose; LDL, low-density lipoprotein;
T2D, type 2 diabetes.
                                                                 
FIG. 2. Frequency distribution of the rs4841132 A allele in 1,127
Italian patients with NAFLD stratified by the presence of HCC.
Comparisons were performed by logistic regression setting HCC as
the dependent variable, and the association with the PPP1R3B vari-
ant was analyzed assuming an additive model. Abbreviations: AA,
homozygotes for the A allele; GA, heterozygotes; GG, homozygotes
for the G allele.
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suggest that the rs4841132 variation does not protect
against HCC independently of hepatic fat accumula-
tion and fibrosis development.
PPP1R3B GENE VARIATION IS
NOT ASSOCIATED WITH
INCREASED LIVER DISEASE RISK
IN THE UNITED KINGDOM
BIOBANK COHORT
We next examined the impact of the rs4841132
minor A allele on liver disease and metabolic traits in
the United Kingdom Biobank cohort, which is repre-
sentative of the general population (N 5 500,000;
Table 5). Here, we did not find any significant associa-
tion between the minor A allele and the risk of liver
disease. These findings suggest that carriage of the A
allele does not reduce the predisposition to develop
liver disease at the population level, despite seeming to
protect against the development of NAFLD in high-
risk individuals. However, consistent with results
observed in the LBC, the A allele was associated with
lower circulating cholesterol levels (P5 8.43 10–8).
PPP1R3B rs4841132 IMPACTS ON
PPP1R3B AND LOC157273
EXPRESSION
The rs4841132 variant is located in exon 2 of
LOC157273, a liver-specific long noncoding RNA,
175 kb upstream of the PPP1R3B gene, which encodes
a protein that promotes hepatic glycogen synthesis. To
determine whether the epidemiological association of
rs4841132 with hepatic steatosis is mediated by modu-
lation of transcription at this locus, we examined the
hepatic expression of LOC157273, PPP1R3B, and
tankyrase (TNKS) in a subset of patients with available
liver samples (n 5 125; Fig. 3A). The rs4841132 A
allele was associated with higher PPP1R3B messenger
RNA levels (P 5 0.04) and with reduced LOC157273
expression (P 5 0.008), whereas TNKS expression was
not affected (P value not significant).
Next, we assessed whether the PPP1R3B variation
was associated with altered expression of genes
involved in hepatic lipid metabolism. Notably, we
found that the minor A allele was associated with up-
regulation of peroxisome proliferator-activated receptor
alpha (P 5 0.004), whereas expressions of sterol regu-
latory element binding protein 1 and 2, microsomal
triglyceride transfer protein, and apolipoprotein B were
not affected (Fig. 3B).
Gene set enrichment analysis on differentially
expressed genes (n 5 1,060; nominal P < 0.05)
revealed down-regulation of several pathways related
to cell cycle and inflammation in patients who carried
the A allele. Consistently, we found a lower expression
of genes involved in inflammation and fibrogenesis,
cholesterol homeostasis, oxidative phosphorylation,
and glycolysis. We also found a nonsignificant down-
regulation of other metabolic pathways, including fatty
acid metabolism, phosphoinositide 3-kinase–protein
TABLE 4. INDEPENDENT PREDICTORS OF NAFLD-HCC IN 1,127 PATIENTS WITH NAFLD (CASES 5 132)
Model 1 Model 2
OR 95% CI P Value OR 95% CI P Value
Age, years 1.18 1.13-1.22 <0.0001 1.18 1.09-1.28 <0.0001
Sex, M 1.21 0.65-2.26 0.54 0.37 0.11-1.30 0.12
BMI, kg/m2 0.92 0.87-0.96 0.002 0.89 0.78-1.02 0.09
IFG/T2DM, yes 4.61 2.56-8.28 <0.0001 4.2 1.07-16.5 0.04
PNPLA3, I148M alleles 1.68 1.14-2.46 0.008 1.14 0.51-2.53 0.75
Advanced fibrosis, F3-F4 NA NA NA 91.4 10.6-790 <0.0001
PPPR13B rs4841132, A alleles 0.22 0.07-0.70 0.01 1.76 0.30-10.3 0.53
Comparisons were performed by logistic regression analysis setting HCC as the dependent variable. Model 1 was adjusted for age,
sex, BMI and T2DM, PNPLA3, TM6SF2, MBOAT7 rs643718, and PPP1R3B rs4841132 genetic variants. Model 2 was further
adjusted for presence of advanced fibrosis.
Abbreviations: BMI, body mass index; IFG, impaired fasting glucose; NA, not addressed; T2DM, type 2 diabetes mellitus.
TABLE 5. ASSOCIATION OF THE PPP1R3B VARIANT
WITH LIVER-RELATED OUTCOMES IN THE
UNITED KINGDOM BIOBANK COHORT
(N 5 500,000)
Phenotype n Cases Beta P value
K70: Alcoholic liver
disease
808 –0.00014799 0.39
K74: Fibrosis and
cirrhosis of liver
805 –0.0001773 0.30
K75: Other inflammatory
liver diseases
662 –0.00026552 0.09
K76: Other diseases
of liver
3,351 0.00035659 0.31
High cholesterol 50,421 –0.0064655 8.4 3 10–8
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kinase B–mammalian target of rapamycin, and lipo-
genesis (adipogenesis). Gene set enrichment analysis
results are summarized in Fig. 3C and Supporting
Table S5.
Finally, to further investigate the mechanism whereby
the rs4841132 variation protects against hepatic fat
accumulation, we performed a gene expression differen-
tial analysis of the whole transcriptome in patients car-
rying the A allele (n 5 19) compared to noncarriers (n
5 106). The analysis revealed that after adjustment for
the false discovery rate the expression of PLEXIN A4
(PLXNA4) and protein kinase, membrane-associated
tyrosine/threonine 1 (PKMYT1) was lower in carriers of
the A allele (P 5 1.3 3 10–5 and P 5 2.1 3 10–5,
respectively; Supporting Table S6).
Discussion
In this study, we examined whether PPP1R3B gene
variation influences the susceptibility to liver damage
in European individuals at high risk of NASH. Our
results suggest that the minor rs4841132 A allele is
associated with a reduced risk of histologic steatosis,
which also resulted in protection against clinically sig-
nificant fibrosis and HCC. Although the direction of
the association is protective and the variant is rarer, the
size effect was marked, making it very similar to that of
the PNPLA3 I148M variant on these three major out-
comes. Despite previous contrasting evidence,(8-13)
these novel data lend strong support to the hypothesis
that the PPP1R3B variation does protect against
hepatic fat accumulation, at least in at-risk individuals.
Furthermore, they support the notion that steatosis is a
major driver of liver disease progression to fibrosis(7)
and HCC(18) in individuals with NAFLD.
However, in the United Kingdom Biobank cohort, a
well-powered population study, the A allele had a neu-
tral impact on liver disease risk. It might be speculated
the protective effect of the rs4841132 A allele on stea-
tosis development can be observed only in individuals
at high baseline risk for NASH and/or in the presence
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FIG. 3. Gene expression in human liver samples collected from liver biopsies was evaluated by transcriptome analysis. (A) PPP1R3B,
LOC157273, TNKS; (B) beta-oxidation (PPARa), lipogenesis (SREBP1c), cholesterol synthesis (SREBP2), and lipoprotein secretion
(MTTP, APOB). *P < 0.05, **P < 0.01 compared to noncarriers (n 5 125). (C) Hallmark molecular functions enriched in patients who
carried the rs4841132 A allele, by RNA sequencing analysis. Bar plots show the gene set enrichment analysis hallmark gene sets that
were found down-regulated (FDR <0.1). Light blue bars indicate gene sets slightly below the significance (FDR between 0.1 and 0.6).
Bars were ordered by normalized enrichment score that indicated the strength of the enrichment. Data are presented as beta
coefficient6 SE. Abbreviations: AA, homozygotes for the A allele; APOB apolipoprotein B; AU, arbitrary unit; FDR, false discovery
rate; GA, heterozygotes; GG, homozygotes for the G allele; il2 stat5, interleukin 2 signal transducer and activator of transcription
5; mRNA, messenger RNA; mtorc1, mammalian target of rapamycin complex 1; MTTP, microsomal triglyceride transfer protein; nfkb,
nuclear factor kappa b; pi3k akt mtor; phosphoinositide 3-kinase–protein kinase B–mammalian target of rapamycin; PPARa, peroxisome
proliferator-activated receptor alpha; SREBP, sterol regulatory element binding protein; tnfa, tumor necrosis factor a; TNKS, tankyrase.
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of unknown environmental triggers. Alternatively, in
individuals at lower risk of NAFLD, predisposition to
glycogen accumulation in carriers of the A allele may
offset the protective effect on hepatic fat accumulation.
Indeed, in two other population studies, namely the
Copenhagen City Heart Study and in the Dallas Liver
Study, carriage of the A allele was borderline associated
with an increased risk of a composite outcome of liver-
related outcomes.(9) Therefore, a limitation of this
study is that we could not assess hepatic glycogen
content.
Concerning the mechanism underpinning the
epidemiological association, we confirmed previous
findings indicating that rs4841132 variation deter-
mines down-regulation of the expression of
LOC157273 as well as and increased levels of
PPP1R3B.(9) However, we could not demonstrate
whether this is mediated by an alteration of the chro-
matin structure of the whole locus or LOC157273 con-
trols PPP1R3B transcription.
It is tempting to speculate that higher expression of
PPP1R3B would favor energy storage under the form
of glycogen in the liver.(9) This may lead to shunting of
glucose to glycogen synthesis from glycolysis and sup-
pression of de novo lipogenesis in carriers of the protec-
tive variant. Interestingly, although we did not directly
measure lipid fluxes, our novel gene expression data
from transcriptomic analysis suggest that carriers of the
variant had reduced glycolysis and lipid oxidation,
which are associated with reduced activation of inflam-
matory and fibrogenic pathways. However, we cannot
rule out that LOC157273 may directly affect the
expression of genes involved in steatosis development
and lipid handling. The association with down-
regulation of cholesterol metabolism genes is consis-
tent with the reduced circulating levels of cholesterol
in severely obese individuals carrying the A allele,
which was also confirmed at the population level both
in the United Kingdom Biobank and in previous stud-
ies.(8) Moreover, differential analysis of gene expression
revealed that two genes involved in tumor progression
and inflammation(26,27) were significantly down-
regulated in patients who carried the A allele.
This study has other limitations. These include
semiquantitative assessment of hepatic fat accumula-
tion by histology, lack of prospective assessment of the
impact of the variant on disease outcomes, and lack of
availability of individual patient data in the United
Kingdom Biobank cohort, precluding a formal evalua-
tion of the interaction between PPP1R3B and adipos-
ity in determining the risk of liver disease.
Furthermore, results are only applicable to European
individuals.
In conclusion, rs4841132 variation influencing
PPP1R3B expression is associated with protection
against hepatic steatosis and fibrosis in individuals at
high risk of NAFLD and against dyslipidemia. The
mechanism seems related to modulation of hepatic
lipid metabolism.
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